INTRODUCTION
Thrombopoietin (TPO, c-mpl ligand) [10] [11] [12] [13] is the major regulator of both megakaryopoiesis and platelet production. TPO is a glycoprotein, which consists of two distinct domains. The N-terminal domain has a receptor-binding site for thrombocytotic activity and the C-terminal domain contains several N-linked sugar chains. TPO receptor (c-mpl, MPL) is a member of the hematopoietic receptor superfamily, which is a type I membrane protein having both conserved cystein residues and a WSXWS box in the extracellular domain. Binding of TPO and MPL triggers the homodimerization of receptors and transmits both proliferation and differentiation signals.
Since the identification and cloning of TPO, two forms of recombinant human TPO, the full length molecule (rhTPO) and the truncated molecule known as pegylated recombinant human megakaryocyte growth and development factor (PEG-rhMGDF), have been evaluated in clinical trials for cancer patients with myelosuppressive chemotherapy.
Early clinical trials demonstrated their clinical safety and platelet-stimulating activity leading to attenuate chemotherapy-induced severe thrombocytopenia and reduce the need for platelet transfusions 14 . However, in this setting, the optimal schedule of TPO administration depends on the length of the regimen and anticipated timing of platelet nadir.
For personal use only. on . by guest www.bloodjournal.org From Furthermore, the development of neutralizing antibodies and clinically significant thrombocytopenia in some patients who received PEG-rhMGDF has led to discontinuation of its clinical trials [15] [16] . Although antibodies against rhTPO were non-neutralizing and transient, administration of rhTPO might also risk the development of neutralizing antibodies 17 against endogenous TPO.
One of the approaches to overcome this antigenic problem of the recombinant TPOs is to generate agonist antibodies 18 , which induce the receptor dimerization leading to signal transduction in the target cells. We have generated the anti-MPL antibodies and converted whole IgG to minibodies. These minibodies, diabody or sc(Fv)2, dramatically increased the agonist activity in TPO dependent cell proliferation assay. The minibody demonstrated a similar agonist activity as natural ligand TPO. At the same time, one of the diabodies had an agonist activity against some of the mutated MPLs derived from CAMT patients. The agonist minibodies will be desirable candidates for TPO mimics to clinically evaluate their therapeutic value without any risk of generating neutralizing antibodies against endogenous TPO.
For personal use only. on . by guest www.bloodjournal.org From Hybridomas were cultured with HAT medium and the supernatants were screened with ELISA and TPO dependent cell (BaF/human MPL) proliferation assay. Anti-MPL monoclonal antibodies were purified by affinity-chromatography on protein G-Sepharose (Amersham) and dialyzed against PBS.
MATERIALS AND METHODS

Immunization
Minibody construction
cDNAs of both the heavy chain variable region (VH) and light chain variable region (VL) were amplified from total RNA of hybridomas by the 5'-Race Method (SMART RACE cDNA amplification kit, Clontech) using specific primers. After determination of the DNA sequence, VH and VL fragments were joined by 5-mer-peptide linker (GGGGS) and the C-terminal end of VL was attached to the Flag Tag sequence (DYKDDDDK). This fragment was subcloned into pCXND3 vector 19 , which was a derivative of pCXN vector containing the DHFR expression unit, and it was termed pCXND3-VB22Bdb. hours at 37°C in 5% CO 2 , 10 µl of the cell count reagent, WST-8 (2-(2-methoxy-
(Nacalai tesque) 20 was added, and further cultured for 2 hours at 37°C in 5% CO 2 .
Absorbance at 450 nm and 655 nm was measured.
M-07e cells were suspended at 5 × 10 5 cells in 50 µl of RPMI 1640/10%FCS medium, and 50 µl of serially diluted samples was added. After being cultured for 48 hours at 37°C in 5% CO2, 10 µl of the cell count reagent, WST-8 (Nacalai tesque) was added, and further cultured for 4 hours at 37°C in 5% CO2. Absorbance at 450 nm and 655 nm was measured. 
In vivo evaluation
First, three SNPs in the cynomolgus monkey MPL gene were identified, and each cDNA was transfected into Ba/F3 cells to establish TPO dependent cell lines. These Ba/F3 cell lines showed slightly different growth sensitivity against rhTPO in the proliferation assays, suggesting that these SNPs might affect the function of MPL. On the other hand, interestingly, VB22B minibodies did not show any difference in the proliferation assays, suggesting that dimerization induced by VB22B binding may not be affected by the SNPs.
Briefly, two groups of three cynomolgus monkeys were administered daily subcutaneous injection with either 1.9 nmol/kg VB22B sc(Fv)2 or vehicle alone. Two groups of three cynomolgus monkeys were administrated daily intravenous injection with 0.11 nmol/kg rhTPO or vehicle alone for 14 days. Blood samples were collected before and after administration of the drug or the vehicle. The number of platelets, hematocrit, and white blood cell were measured by sysmex (SysmexF-820). for human MPL, their growth stimulating activities against the TPO dependent BaF/human MPL cells were very weak (Fig .1B) .
RESULTS
Characterization
Therefore, monoclonal antibodies were genetically engineered to be minibodies 22 could dramatically improve its agonist activity even in the cases when parent IgGs had no agonist activity at all (data not shown). Among these monoclonal antibodies, VB22B (IgG2b/ ) and TA136 (IgG2a/ ) were selected for further characterization.
VB22B bound to both human and monkey MPLs expressed in CHO cells with high affinity (~10 nM), although its agonist activity was very weak in the TPO dependent BaF3 cell proliferation assays (Fig. 1B) . For human MPL, the conversion to a diabody dramatically increased its agonist activity, but not for monkey MPL. However, the conversion of diabody to sc (Fv) 2, could improve its agonist activities especially against monkey MPL. Finally, EC50s of VB22B sc(Fv)2 were about 30 pmol in both BaF/human MPL and BaF/monkey MPL. Very importantly, binding affinities of whole antibody and minibodies were almost similar, which suggested that this drastic improvement of agonist activity might be due to structural features, but not affinity change.
Functional characterization of VB22B sc(Fv)2.
To confirm whether VB22B sc(Fv)2 correctly mimics the biological functions of TPO, these were compared as follows. In an authentic proliferation assay with a TPO dependent cell line M-07e 23 derived from human megakaryoblastic leukemia, VB22B sc(Fv)2 stimulated the cellular growth as well as rhTPO ( Fig. 2A) . In a megakaryocyte differentiation assay with CD34 positive progenitor cells prepared from human bone marrow 24 , VB22B sc(Fv)2 increased CD41 (GPIIb) positive cells, which represent a population of megakaryocyte lineage, in a dose dependent manner in the presence of interleukin-3 (Fig. 2B) , whereas a population of myeloid specific marker CD33 25 positive cells was not changed (Data not shown). This might suggest that VB22B sc(Fv)2 specifically functioned as a megakaryocyte differentiation lineage. In order to molecularly confirm functional similarities of VB22B sc(Fv)2 or rhTPO, M-07e cells after being stimulated by VB22B sc(Fv)2 or rhTPO were subjected to a phosphorylation analysis 26 .
Indeed, all three molecules JAK2, STAT3, and STAT5b were phosphorylated by VB22B sc(Fv)2 as efficiently as rhTPO (Fig. 2C) , which suggested that the molecular mechanism of receptor activation by VB22B sc(Fv)2 was almost the same as that by TPO. At the same time, Mpl was also phosphorylated by VB22B sc(Fv)2 (Data not shown).
TA136 activates mutated Mpl derived from CAMT.
Since VB22B sc(Fv)2 failed to stimulate the cellular growth through mutated MPLs (Fig.   3 ), we screened and characterized minibodies, which could bind the dysfunctional MPL due (Fig. 3) . However, since TA136 sc(Fv)2 had no cross-reactivity with any other species, we could not further characterize in animal models.
In vivo activity of VB22B sc(Fv)2
Preliminary PK studies showed that serum half-life (T 1/2 ) of VB22B sc(Fv)2 was calculated as approximately 8 h or 9 h in normal cynomolgus monkeys for intravenous or subcutaneous administrations, respectively. According to the results of nonconpartment parameters (T 1/2 , AUC) 1.9 nmol/kg/day of VB22B sc(Fv)2 and 0.11 nmol/kg/day of rhTPO as positive control were administered subcutaneously and intravenously, respectively, for
For personal use only. on . by guest www.bloodjournal.org From -14 -14 days. Clearly, VB22B sc(Fv)2 increased the platelet counts as rhTPO did. (Fig. 4) . No significant changes in other blood parameters were observed (data not shown). Furthermore, there were no significant differences in the platelet aggregation between the platelets produced in vivo by VB22B sc(Fv)2 and normal platelets in vitro assay after adenosine diphosphate (ADP) stimulation (Data not shown). This indicated that platelets produced in vivo by VB22B sc(Fv)2 and rhTPO were functionally comparable. After day 40, the platelet counts of the all three monkeys administered rhTPO significantly reduced to approximately 10-30%, and had not recovered by Day 160 to the basal levels before administration of rhTPO. This suggested that the function of endogenous TPO might be continuously inhibited. Indeed, anti-rhTPO antibodies were detected in the serum from the monkey administered by rhTPO. Whereas, no monkeys administered VB22B sc(Fv)2 showed any reduction in the platelet counts resulting in thrombocytopenia.
Discussion
We have generated anti-Mpl antibodies and converted them to minibodies, such as diabody and sc(Fv)2. Minibodies dramatically increased agonist activity. VB22B sc(Fv)2 indicated a similar activity to the natural ligand TPO in vitro in both proliferation and differentiation assays. Moreover, in the in vivo evaluation, VB22B sc(Fv)2 significantly increased peripheral platelet numbers in monkey without any neutralizing antibodies against endogenous TPO. On the other hand, another minibody, TA136 sc(Fv)2 had an agonist activity against two types of mutated Mpl derived from CAMT patients. This is also the first report that agonist antibodies, especially minibodies, could provide innovative therapeutics for patients with the disease caused by the receptor dysfunctions. It is not necessary that binding sites of agonist antibodies should be the same as that of TPO.
Several epitopes facilitated in the receptor dimerization may be existed in the MPL. Indeed VB22B bound to the domain I sequence of MPL, whereas TA136 recognized a tertially structure of MPL. Currently we are analyzing epitopes in more detail and X-ray crystarography of minibodies, and thus in the near future we will report structural features and relationship between minibodies and receptors.
It should be worthwhile to clinically evaluate agonist minibodies such as humanized Finally, one of the advantages of minibodies in clinical applications compared with whole antibodies is that the control of serum concentration of minibodies in patients could be easier due to their short half-life. This agonist minibody technology is also applicable for the generation of cell death (apoptosis / necrosis) inducing minibodies, which efficiently 
ACKNOWLEDGMENT
We would like to thank Dr. Shigekazu Nagata for thoughtful discussion. We would like to For personal use only. on . by guest www.bloodjournal.org From
